SLRX Salarius Pharmaceuticals Inc
12,118
$0.50
$0.0074
(1.46%)
| Watchers | 12,118 |
| 52-Wk Low | $0.43 |
| 52-Wk High | $1.87 |
| Market Cap | $2.39M |
| Volume | 4,306.00 |
| 52-Wk High | $1.87 |
| 52-Wk Low | $0.43 |
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketBenzinga • about 2 months ago
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today's pre-market trading following fourth-quarter results.
read more...
Share to Feed
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
read more...
Titoli in rialzo
Le azioni di Salarius Pharmaceuticals (NASDAQ:SLRX) sono cresciute del 33,90% a 0,83 dollari durante la sessione after-market di venerd .
Il titolo Masimo (NASDAQ:MASI) ha osservato...
Acciones al alza
Salarius Pharmaceuticals (NASDAQ:SLRX) experimentaron un repunte del 35,29% para establecerse en los 0,84 d lares durante la sesi n del after-market del viernes.
Masimo (NASDAQ:MASI...
Salarius Pharmaceuticals GAAP EPS of -$3.84...
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...
Company implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from...
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan...
Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and...